DelveInsight’s “Chronic Venous Ulceration Market Insight, Epidemiology and Market Forecast–2034” report delivers an in-depth analysis of Chronic Venous Ulceration epidemiology, market, and clinical development in Chronic Venous Ulceration. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the Chronic Venous Ulceration market trends in the United States, EU4 (Germany, Spain, Italy, and France) the United Kingdom, and Japan.
Discover Key Insights into the Chronic Venous Ulceration Market with DelveInsight’s In-Depth Report @ Chronic Venous Ulceration Market Size
Key Takeaways from the Chronic Venous Ulceration Market Report
- In 2023, the United States accounted for the highest prevalent cases of venous ulcers.
- In EU4 and the UK, the total diagnosed prevalent population of chronic venous ulcers was observed to be maximum in Germany followed by France. While the least number of cases were observed in Spain in 2023.
- Chronic venous insufficiency is the cause of nearly 80% of lower leg ulcers.
- In the United States, the diagnosed prevalence of venous ulcers was highest in the age group of >70 years
- As per the estimates, it has been observed that venous ulcers are more common in females as compared to males.
- The Chronic Venous Ulceration Companies such as Array Biopharma/Pfizer, Merck, Bristol-Myers Squibb, Eli Lilly and Company, Taiho Oncology, Sumitomo Dainippon Pharma, Hutchison Medipharma Limited, G1 Therapeutics, Isofol Medical, AB Science, Effector Therapeutics, and others.
- Promising Chronic Venous Ulceration Therapies such as P-TEV, VenoValve, EnVVe, SONOVEIN, and others
Stay ahead in the Chronic Venous Ulceration Therapeutics Market with DelveInsight’s Strategic Report @ Chronic Venous Ulceration Market Outlook
Chronic Venous Ulceration Epidemiology Segmentation in the 7MM
- Total Chronic Venous Ulceration prevalent cases
- Chronic Venous Ulceration diagnosed prevalent cases
- Chronic Venous Ulceration diagnosed prevalent cases
- Chronic Venous Ulceration type-specific cases
- Chronic Venous Ulceration gender-specific cases
- Chronic Venous Ulceration age-specific cases
Download the report to understand which factors are driving Chronic Venous Ulceration epidemiology trends @ Chronic Venous Ulceration Prevalence
Chronic Venous Ulceration Marketed Drugs
- AMESANAR (allogeneic ABCB5-positive mesenchymal stromal cells/Allo-APZ2-CVU): RHEACELL
Allogeneic ABCB5-positive Stem Cells/ Allo-APZ2-CVU developed by Rheacell, a subsidiary of Ticeba, for the treatment of Chronic Venous Ulcers. Exerting immunomodulatory and anti-inflammatory effects involving several pathways, human dermal ABCB5+ MSCs/ Allo-APZ2-CVU can be reliably isolated, expanded, and manufactured as a homogenous MSC population for future in-human use as an advanced-therapy medicinal product (ATMP). In October 2021, AMESANAR was granted national approval under section 4b of the German Medicinal Products Act to be used in patients with chronic wounds caused by chronic venous insufficiency. In December 2021, the product was listed on the website of Germany’s Federal Institute for Vaccines and Biomedicines.
Chronic Venous Ulceration Emerging Drugs
- EscharEx: MediWound
MediWound’s EscharEx is a topical biological drug candidate for the debridement of chronic and other hard-to-heal wounds using the same proteolytic enzyme technology as NEXOBRID. It is a mixture of proteolytic enzymes for the management of the debridement of chronic and other hard-to-heal wounds. It is easy to use, and it is a non-surgical topical application that demonstrated safety and efficacy in the debriding of chronic wounds in several etiologies within a few daily applications. Recently Phase II clinical study of EscharEx for the debridement of venous leg ulcers (VLUs) also received positive results.
- P-TEV (personalized tissue-engineered vein): VERIGRAFT
VERIGRAFT’S lead product, P-TEV is a personalized tissue-engineered vein (P-TEV) graft for use in surgical implantation to replace a defective or missing part of a patient’s vein. The P-TEV drug substance consists of an extracellular matrix (ECM) scaffold in the form of a decellularized (DC) allogeneic vein scaffold which is populated with autologous components from the patient’s peripheral whole blood (PWB) in an ATMP manufacturing process performed under GMP. The company is currently evaluating the product in a Phase I (NCT03784131) trial in patients with severe chronic venous insufficiency.
Get In-Depth Knowledge on Chronic Venous Ulceration Market Trends and Forecasts with DelveInsight @ Chronic Venous Ulceration Treatment Market
Chronic Venous Ulceration Market Outlook
The current treatment modalities for venous ulcers include conservative management, mechanical modalities, medications, advanced wound therapy, and surgical options. Although the main goal of treatment is ulcer healing, secondary goals include reducing edema and preventing recurrence. Evidence-based treatment options for venous ulcers include leg elevation, compression therapy, dressings, pentoxifylline, and aspirin therapy. Topical antiseptics, including cadexomer iodine (Iodosorb), povidone-iodine (Betadine), peroxide-based preparations, honey-based preparations, and silver, have also been used to treat venous ulcers. Surgical management may be considered for ulcers that are large, of prolonged duration, or refractory to conservative measures. AMESANAR is the only product that has been granted national approval under section 4b of the German Medicinal Products Act to be used in patients with chronic wounds caused by chronic venous insufficiency.
Scope of the Chronic Venous Ulceration Market Report
- Coverage- 7MM
- Study Period- 2020-2034
- Chronic Venous Ulceration Companies- Array Biopharma/Pfizer, Merck, Bristol-Myers Squibb, Eli Lilly and Company, Taiho Oncology, Sumitomo Dainippon Pharma, Hutchison Medipharma Limited, G1 Therapeutics, Isofol Medical, AB Science, Effector Therapeutics, and others.
- Chronic Venous Ulceration Therapies- P-TEV, VenoValve, EnVVe, SONOVEIN, and others
- Chronic Venous Ulceration Market Dynamics: Chronic Venous Ulceration Market Drivers and Barriers
- Chronic Venous Ulceration Unmet Needs, KOL’s views, Analyst’s views, Chronic Venous Ulceration Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Chronic Venous Ulceration Market Report @ Chronic Venous Ulceration Market Drivers and Barriers
Table of content
- Key Insights
- Report Introduction
- Executive Summary
- Key Events
- Epidemiology and Market Forecast Methodology
- Chronic venous ulceration Market Overview at a Glance
- Disease Background and Overview
- Treatment
- Epidemiology and Patient Population
- Patient Journey
- Marketed Drugs
- Emerging Drugs
- Chronic venous ulceration: Seven Major Market Analysis
- Unmet Needs
- SWOT Analysis
- KOL views
- Market Access and Reimbursement
- Appendix
- DelveInsight Capabilities
- Disclaimer
- About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/respiratory-domain-conference-coverage